Clinical trials: Nonalcoholic Steatohepatitis
Cardiovascular Disease
The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health
The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease
- Trial name
- Almonds (NCT02907684)
- Testing
- Almonds, Muffins/Crackers
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- King's College London
Nonalcoholic Fatty Liver Disease
Dietary Treatment Study of Pediatric NAFLD
This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU).
- Trial name
- DTS (NCT02513121)
- Testing
- Dietary modification
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
NAFLD
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma.
- Trial name
- NCT04861571
- Testing
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Hepatitis
The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity.
- Trial name
- NCT01068444
- Testing
- Pioglitazone
- Where
- 2 sites in Taiwan
- Volunteers
- 90 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metabolic Syndrome
Effectiveness of Self-Management Skills for Metabolic Syndrome Fatty Liver Disease Adults
The multidimensional self-management intervention program focusing on healthy dietary habit and exercise effectively prevents metabolic syndrome.
- Trial name
- NCT05472298
- Testing
- self-management intervention
- Where
- Taiwan
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Chang Gung University of Science and Technology
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
NAFLD
NAFLD in Patient of Hypothyroidism
Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population.
- Trial name
- NCT05813301
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Cardiovascular Diseases, Lipid Disorder
SRMA of the Effect of Soy Milk vs Cow's Milk on Cardiometabolic Outcomes
Dairy consumption has shown associations with decreased incidence of cardiometabolic diseases. With the growing interest in plant-based eating, and the mounting evidence for the cardiovascular benefits of plant forward diets…
- Conditions
- Cardiovascular Diseases, Lipid Disorder, Metabolic Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05637866
- Testing
- Soy milk
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
NASH - Nonalcoholic Steatohepatitis, NAS
Hepatic Energy Fluxes in NASH and NAS Patients
Diseases along the nonalcoholic fatty liver disease spectrum, which are tightly coupled to the obesity epidemic, are soon to become the commonest indication for liver transplantation in the United States.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss
- Trial name
- NCT03997422
- Testing
- Vertical Sleeve Gastrectomy (VSG)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Non-Alcoholic Fatty Liver Disease
Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound
Liver cells play a major role in the regulation of lipid metabolism. They are the principal location for lipoprotein and cholesterol synthesis.
- Trial name
- NCT05486429
- Testing
- Abdominal ultrasound and lipid profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
NAFLD
Fighting Fatty Liver in India
This study aims to build capacity in India by: 1. Developing tailored protocol methodologies for research including technical capability in imaging (MRI/S protocols \& customised software), dietary intervention delivery, dietary…
- Trial name
- FFL (NCT03844165)
- Testing
- Diet change (red rice), Yoga
- Where
- India
- Volunteers
- 84 people
- Sponsor
- University of Nottingham
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD)
Tesamorelin Effects on Liver Fat and Histology in HIV
Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection.
- Conditions
- Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT02196831
- Testing
- tesamorelin
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Liver Fibrosis
A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor
Soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease.
- Trial name
- NCT00941902
- Where
- Israel
- Volunteers
- 148 people
- Sponsor
- Ziv Hospital
Non-Alcoholic Fatty Liver Disease, Central Obesity
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns.
- Trial name
- NCT03912272
- Testing
- High-intensity Interval Training, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
NAFLD
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, which is one of the most common forms of chronic liver disease in developed countries.
- Trial name
- NCT02083159
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Korea University
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.